Insulet Corporation (PODD) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS
Insulet Corporation (NASDAQ:PODD) issued its earnings results on Thursday. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.06, Briefing.com reports. The company had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. Insulet Corporation had a negative net margin of 6.66% and a negative return on equity of 45.64%. Insulet Corporation’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) EPS.
Shares of Insulet Corporation (NASDAQ:PODD) traded up $11.03 during midday trading on Friday, hitting $69.45. 3,400,908 shares of the stock traded hands, compared to its average volume of 445,758.
Several brokerages recently weighed in on PODD. Oppenheimer Holdings, Inc. set a $55.00 target price on shares of Insulet Corporation and gave the stock a “hold” rating in a report on Friday, August 4th. Morgan Stanley upped their target price on shares of Insulet Corporation from $55.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday. Robert W. Baird upped their target price on shares of Insulet Corporation from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Friday. Jefferies Group LLC increased their price objective on shares of Insulet Corporation from $58.00 to $67.00 and gave the company a “buy” rating in a report on Friday. Finally, Northland Securities reissued a “buy” rating on shares of Insulet Corporation in a report on Friday, August 4th. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $58.87.
In other Insulet Corporation news, EVP Charles Alpuche bought 2,500 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were purchased at an average cost of $58.08 per share, for a total transaction of $145,200.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.90% of the stock is currently owned by corporate insiders.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.